KR102888596B1 - 포스포-타우 항체 및 사용 방법 - Google Patents

포스포-타우 항체 및 사용 방법

Info

Publication number
KR102888596B1
KR102888596B1 KR1020257022547A KR20257022547A KR102888596B1 KR 102888596 B1 KR102888596 B1 KR 102888596B1 KR 1020257022547 A KR1020257022547 A KR 1020257022547A KR 20257022547 A KR20257022547 A KR 20257022547A KR 102888596 B1 KR102888596 B1 KR 102888596B1
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
tau
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020257022547A
Other languages
English (en)
Korean (ko)
Other versions
KR20250108128A (ko
Inventor
안드레아스 제로민
크리시 벤카트
Original Assignee
알즈패스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알즈패스, 인크. filed Critical 알즈패스, 인크.
Priority claimed from KR1020247011209A external-priority patent/KR102959196B1/ko
Publication of KR20250108128A publication Critical patent/KR20250108128A/ko
Application granted granted Critical
Publication of KR102888596B1 publication Critical patent/KR102888596B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96416—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020257022547A 2021-09-09 2022-09-08 포스포-타우 항체 및 사용 방법 Active KR102888596B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163242437P 2021-09-09 2021-09-09
US63/242,437 2021-09-09
KR1020247011209A KR102959196B1 (ko) 2021-09-09 2022-09-08 포스포-타우 항체 및 사용 방법
PCT/US2022/042963 WO2023039107A2 (en) 2021-09-09 2022-09-08 Phospho-tau antibodies and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020247011209A Division KR102959196B1 (ko) 2021-09-09 2022-09-08 포스포-타우 항체 및 사용 방법

Publications (2)

Publication Number Publication Date
KR20250108128A KR20250108128A (ko) 2025-07-15
KR102888596B1 true KR102888596B1 (ko) 2025-11-20

Family

ID=85507770

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257022547A Active KR102888596B1 (ko) 2021-09-09 2022-09-08 포스포-타우 항체 및 사용 방법

Country Status (7)

Country Link
US (3) US12276671B2 (https=)
EP (1) EP4399524A4 (https=)
JP (3) JP7836885B2 (https=)
KR (1) KR102888596B1 (https=)
CN (1) CN118235043A (https=)
CA (1) CA3231228A1 (https=)
WO (1) WO2023039107A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023039107A2 (en) 2021-09-09 2023-03-16 Alzpath, Inc. Phospho-tau antibodies and methods of use
KR20250173598A (ko) * 2023-03-16 2025-12-10 알즈패스, 인크. 신경퇴행성 질환의 진단 및 치료 방법
CN119470917A (zh) * 2024-11-14 2025-02-18 苏州智研医康医疗科技有限公司 一种检测人血中阿尔茨海默病相关蛋白的试剂盒及检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US20040219509A1 (en) 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7604956B2 (en) 2004-03-01 2009-10-20 Biotraces, Inc. Supersensitive immunoassays
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
US7914734B2 (en) 2007-12-19 2011-03-29 Singulex, Inc. Scanning analyzer for single molecule detection and methods of use
US20110177509A1 (en) 2008-07-23 2011-07-21 The Washington University Risk factors and a therapeutic target for neurodegenerative disorders
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
JP2013518927A (ja) * 2010-02-09 2013-05-23 ブリストル−マイヤーズ スクイブ カンパニー 免疫アッセイ標準物質およびアッセイ内の校正標準物質を用いる臨床バイオマーカーの測定
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
WO2012142300A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
KR101981351B1 (ko) 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
MX350311B (es) 2011-12-20 2017-09-01 Janssen Biotech Inc Anticuerpos anti-phf-tau y sus usos.
NZ630542A (en) * 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
NZ775762A (en) * 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
GB201518675D0 (en) * 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
US20180080945A1 (en) * 2016-09-20 2018-03-22 Nanosomix, Inc. Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
KR102048987B1 (ko) * 2017-02-22 2019-11-27 한국과학기술연구원 신경퇴행성 장애의 진단을 위한 정보 제공 방법
JP7029718B2 (ja) * 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
WO2019085804A1 (en) 2017-11-02 2019-05-09 Peking University Methods and use for detecting and inhibiting cell-free mg53
EP3706795A4 (en) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
US20200377609A1 (en) 2018-02-14 2020-12-03 Kite Pharma, Inc. Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
WO2020105700A1 (ja) 2018-11-22 2020-05-28 富士レビオ株式会社 抗体コンジュゲート
KR102905634B1 (ko) 2019-05-31 2025-12-30 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법
WO2021178545A1 (en) 2020-03-03 2021-09-10 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Proteomic screening for diseases
CN112505322A (zh) * 2020-10-16 2021-03-16 威海纽普生物技术有限公司 阿尔茨海默病标志物p-Tau217检测试剂盒及其制造方法
US20240003918A1 (en) 2020-11-30 2024-01-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2023039107A2 (en) 2021-09-09 2023-03-16 Alzpath, Inc. Phospho-tau antibodies and methods of use
KR20250173598A (ko) * 2023-03-16 2025-12-10 알즈패스, 인크. 신경퇴행성 질환의 진단 및 치료 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dabramo Cristina et al, Journal of Personalized Medicine, (2020.09.08.), Vol 10, No 3, pp 1-39
Ercan Herbst Ebru et al, Acta Neuropathologica Communications, (2019.12.01.), Vol 7, No 1, pp1-19.

Also Published As

Publication number Publication date
US12276671B2 (en) 2025-04-15
EP4399524A4 (en) 2025-10-08
CN118235043A (zh) 2024-06-21
EP4399524A2 (en) 2024-07-17
US12339290B2 (en) 2025-06-24
CA3231228A1 (en) 2023-03-16
US20250277799A1 (en) 2025-09-04
JP2026034506A (ja) 2026-02-27
KR20240067082A (ko) 2024-05-16
US20240353428A1 (en) 2024-10-24
JP7828500B2 (ja) 2026-03-11
US20240360206A1 (en) 2024-10-31
JP2024534348A (ja) 2024-09-20
WO2023039107A2 (en) 2023-03-16
JP7836885B2 (ja) 2026-03-27
JP2025137567A (ja) 2025-09-19
KR20250108128A (ko) 2025-07-15
WO2023039107A3 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
KR102888596B1 (ko) 포스포-타우 항체 및 사용 방법
US10976325B2 (en) Assays to detect neurodegeneration
CN116348769A (zh) 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定
EP3533459A1 (en) Anti-pla2-gib antibodies and the uses thereof
KR20230154307A (ko) 혈장 및 뇌척수액에서 신경필라멘트 경쇄를 검출하는 방법
JP7308914B2 (ja) ウイルス抗原の血清学的検出方法
JP7830486B2 (ja) オキシントモジュリン結合分子、及びそれらの使用
JP2026509486A (ja) 神経変性障害を診断および処置する方法
KR102959196B1 (ko) 포스포-타우 항체 및 사용 방법
JP2010254663A (ja) 抗ｋｏｄｄｎａポリメラーゼ抗体及びそれを用いた非特異反応の抑制方法
HK40112938A (zh) 磷酸化-tau抗体和使用方法
BR122025017050A2 (pt) Anticorpo anti-tau ou fragmento de ligação ao antígeno do mesmo
Guo et al. Ultrasensitive chemiluminescent detection of plasma Aβ1-40 based on soluble macromolecular signal amplification carrier
WO2012113718A1 (en) A diagnostic method for type ii diabetes
WO2019079970A1 (zh) 一种治疗性抗体的放行检测方法

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D16-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)